These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 11406167)

  • 1. Mechanisms of resistance to cisplatin.
    Kartalou M; Essigmann JM
    Mutat Res; 2001 Jul; 478(1-2):23-43. PubMed ID: 11406167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition of cisplatin adducts by cellular proteins.
    Kartalou M; Essigmann JM
    Mutat Res; 2001 Jul; 478(1-2):1-21. PubMed ID: 11406166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin resistance and oncogenes--a review.
    Dempke W; Voigt W; Grothey A; Hill BT; Schmoll HJ
    Anticancer Drugs; 2000 Apr; 11(4):225-36. PubMed ID: 10898536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin.
    Trimmer EE; Essigmann JM
    Essays Biochem; 1999; 34():191-211. PubMed ID: 10730196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.
    Lanzi C; Perego P; Supino R; Romanelli S; Pensa T; Carenini N; Viano I; Colangelo D; Leone R; Apostoli P; Cassinelli G; Gambetta RA; Zunino F
    Biochem Pharmacol; 1998 Apr; 55(8):1247-54. PubMed ID: 9719480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin.
    Reed E
    Cancer Chemother Biol Response Modif; 1999; 18():144-51. PubMed ID: 10800481
    [No Abstract]   [Full Text] [Related]  

  • 7. Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes.
    Nijwening JH; Kuiken HJ; Beijersbergen RL
    Cell Cycle; 2011 Feb; 10(3):380-6. PubMed ID: 21239890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast.
    McA'Nulty MM; Lippard SJ
    Mutat Res; 1996 Jan; 362(1):75-86. PubMed ID: 8538651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
    Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
    Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.
    Yang Z; Faustino PJ; Andrews PA; Monastra R; Rasmussen AA; Ellison CD; Cullen KJ
    Cancer Chemother Pharmacol; 2000; 46(4):255-62. PubMed ID: 11052622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of amine from platinum(II) complexes: implications for cisplatin inactivation, storage, and resistance.
    Lau JK; Deubel DV
    Chemistry; 2005 Apr; 11(9):2849-55. PubMed ID: 15744707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
    Reardon JT; Vaisman A; Chaney SG; Sancar A
    Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z; Xu Z; Zhu G
    Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.
    Makovec T
    Radiol Oncol; 2019 Mar; 53(2):148-158. PubMed ID: 30956230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical perspectives on platinum resistance.
    Kelland LR
    Drugs; 2000; 59 Suppl 4():1-8; discussion 37-8. PubMed ID: 10864225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advance in studies on molecular mechanisms of cisplatin resistance and intervention with traditional Chinese medicines].
    Liu L; Bian K
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3216-20. PubMed ID: 25522600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
    Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
    Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure.
    Espina M; Corte-Rodríguez M; Aguado L; Montes-Bayón M; Sierra MI; Martínez-Camblor P; Blanco-González E; Sierra LM
    Metallomics; 2017 May; 9(5):564-574. PubMed ID: 28425536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.